PharmAla Provides Comprehensive Investor Update Following Release of Q3 Financial Statement
30 juil. 2024 08h55 HE
|
PharmAla Biotech
PharmAla releases a comprehensive investor update following its Q3 financial release, including highlights such as a 10x revenue increase and patent update
Nxu, Inc. Announces Fourth Quarter and Full Year 2023 Financial Results
01 avr. 2024 06h30 HE
|
Nxu Inc.
MESA, Ariz., April 01, 2024 (GLOBE NEWSWIRE) -- Nxu, Inc. (NASDAQ: NXU) (“Nxu”, “the Company”), a domestic technology company developing and manufacturing innovative EV charging and energy storage...
Nxu Inc. to Report Second Quarter 2023 Financial Results
11 août 2023 06h30 HE
|
Nxu Inc.
MESA, Ariz., Aug. 11, 2023 (GLOBE NEWSWIRE) -- Nxu Inc., (NASDAQ: NXU) (“Nxu”, “the Company”), a vertically integrated technology company creating energy storage and charging solutions for the...
Blue Water Vaccines Reports First Quarter 2022 Financial Results and Recent Business Developments
13 mai 2022 17h01 HE
|
Blue Water Vaccines Inc.
Closed initial public offering of 2,222,222 shares of common stock at a public offering price of $9.00 per share, with aggregate gross proceeds of approximately $20 millionMultiple vaccine candidate...
Cognition Therapeutics Reports Year End 2021 Financial Results and Provides Business Update
30 mars 2022 07h00 HE
|
Cognition Therapeutics, Inc.
- Well capitalized from $52 million IPO and $169 million in grant funding -- Established clinical program in Alzheimer’s disease enhanced by new DLB study and dry AMD program -- Conference call and...
Innate Pharma First Quarter 2020 Report
12 mai 2020 01h00 HE
|
INNATE PHARMA
Cash, cash equivalents and financial assets of the Company amounted to €206.9 millioniFirst patient dosed in avdoralimab (anti-C5aR) Phase II clinical trial in COVID-19 patients with severe...
Zomedica Announces Second Quarter 2019 Financial Results
08 août 2019 16h08 HE
|
Zomedica Pharmaceuticals Corp.
ANN ARBOR, Mich., Aug. 08, 2019 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American:ZOM) (TSX-V:ZOM) (“Zomedica” or “Company”), a veterinary diagnostic and pharmaceutical company,...
Melinta Therapeutics Reports Fourth Quarter and Full-Year 2018 Financial Results
13 mars 2019 16h00 HE
|
Melinta Therapeutics
~ Reports Revenue of $96.4 million, Including Net Product Sales of $46.6 million, for the Full-Year 2018 ~ ~ Net Product Sales of $14.6 million for the Fourth Quarter of 2018, up 32 Percent from...
Melinta Therapeutics to Report Fourth Quarter and Year-End 2018 Financial Results on March 13, 2019
05 mars 2019 08h00 HE
|
Melinta Therapeutics
MORRISTOWN, N.J., March 05, 2019 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to...
Emerald Health Therapeutics Reports 3rd Quarter 2018 Financial Results and Provides Corporate Update
30 nov. 2018 07h00 HE
|
Emerald Health Therapeutics Inc.
VICTORIA, British Columbia, Nov. 30, 2018 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (TSXV:EMH; OTCQX:EMHTF) (“Emerald” or “the Company”) has filed its financial statements and management...